Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 4
2018 6
2019 6
2020 3
2021 8
2022 14
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "RISS Stage III Plasma Cell Myeloma"
Page 1
Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.
D'Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall'Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Bladé Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, Dürig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hernández Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. D'Agostino M, et al. J Clin Oncol. 2022 Oct 10;40(29):3406-3418. doi: 10.1200/JCO.21.02614. Epub 2022 May 23. J Clin Oncol. 2022. PMID: 35605179 Free article.
PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are at intermediate-risk according to the Revised International Staging system (R-ISS), the standard-of-care risk stratification model. . …
PURPOSE: Patients with newly diagnosed multiple myeloma (NDMM) show heterogeneous outcomes, and approximately 60% of them are …
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Palumbo A, et al. J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3. J Clin Oncol. 2015. PMID: 26240224 Free PMC article.
PURPOSE: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify patients with MM. We combined the International Staging System (ISS) with chromosomal abnormalities (CA) detected by interphase fluoresce …
PURPOSE: The clinical outcome of multiple myeloma (MM) is heterogeneous. A simple and reliable tool is needed to stratify pati …
Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.
Chen L, Fan F, Deng J, Xu J, Xu A, Sun C, Hu Y. Chen L, et al. Ann Hematol. 2019 Apr;98(4):963-970. doi: 10.1007/s00277-018-3582-4. Epub 2019 Jan 4. Ann Hematol. 2019. PMID: 30610280
Moreover, 36.2% of patients were at the Revised International Staging System (RISS) stage III when diagnosed. Those patients had significantly shorter PFS and OS compared with patients at RISS stages I and II. In conclusion, IgD myelom …
Moreover, 36.2% of patients were at the Revised International Staging System (RISS) stage III when diagnosed. Th …
Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis.
Bao L, Wang YT, Lu MQ, Chu B, Shi L, Gao S, Fang LJ, Xiang QQ, Ding YH, Liu X, Zhao X, Wang MZ, Chen Y, Hu WK. Bao L, et al. Front Endocrinol (Lausanne). 2023 Apr 27;14:1157969. doi: 10.3389/fendo.2023.1157969. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37181039 Free PMC article.
PURPOSE: Vitamin D deficiency is frequent in patients with multiple myeloma (MM), however, its prognostic relevance in MM was rather inconclusive. ...Compared to the group with a higher vitamin D to beta-CTX ratio, the group with a lower vitamin D to beta-CTX …
PURPOSE: Vitamin D deficiency is frequent in patients with multiple myeloma (MM), however, its prognostic relevance in …
A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.
Grant SJ, Wildes TM, Rosko AE, Silberstein J, Giri S. Grant SJ, et al. Cancer. 2023 Jul 1;129(13):2023-2034. doi: 10.1002/cncr.34760. Epub 2023 Mar 29. Cancer. 2023. PMID: 36989073
BACKGROUND: Despite the increased availability and use of novel therapies for multiple myeloma, early mortality is a pervasive challenge with a significant impact on older adults. ...Among those aged 70 years, ECOG PS 2 and R-ISS stage III remained the …
BACKGROUND: Despite the increased availability and use of novel therapies for multiple myeloma, early mortality is a pervasive …
Exploring the R-ISS stage-specific regular networks in the progression of multiple myeloma at single-cell resolution.
Zhong L, Yang X, Zhou Y, Xiao J, Li H, Tao J, Xi Q, Chu C, Li C, Yang X, Yang C, Zhang Y, Shuai P, Liu Y, Yu M, Shi Y, Hu J, Zhang W, Gong B, Yang Z. Zhong L, et al. Sci China Life Sci. 2022 Sep;65(9):1811-1823. doi: 10.1007/s11427-021-2097-1. Epub 2022 Apr 7. Sci China Life Sci. 2022. PMID: 35437648
The Revised International Staging System (R-ISS) is a simple and powerful prognostic tool for multiple myeloma (MM). ...Plasma cells were clustered into nine groups (P1-P9) based on gene expression, where P1-P5 were almost enriched in stage …
The Revised International Staging System (R-ISS) is a simple and powerful prognostic tool for multiple myeloma ( …
Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.
Li Q, Ai L, Zuo L, Li J, Zhao F, Xu A, Zhang B, Cai L, Hu Y, Sun C. Li Q, et al. Ann Med. 2024 Dec;56(1):2338604. doi: 10.1080/07853890.2024.2338604. Epub 2024 Apr 10. Ann Med. 2024. PMID: 38599340 Free PMC article.
BACKGROUND: Circulating plasma cells (CPCs) are defined by the presence of peripheral blood clonal plasma cells, which would contribute to the progression and dissemination of multiple myeloma (MM). ...Moreover, the increased CPCs were significantly re …
BACKGROUND: Circulating plasma cells (CPCs) are defined by the presence of peripheral blood clonal plasma cells, which would c …
Revised International Staging System (R-ISS) stage-dependent analysis uncovers oncogenes and potential immunotherapeutic targets in multiple myeloma (MM).
Zhong L, Hao P, Zhang Q, Jiang T, Li H, Xiao J, Li C, Luo L, Xie C, Hu J, Wang L, Liu Y, Shi Y, Zhang W, Gong B. Zhong L, et al. Elife. 2022 Oct 31;11:e75340. doi: 10.7554/eLife.75340. Elife. 2022. PMID: 36315425 Free PMC article.
As with many types of cancer, the chance of survival is highest when multiple myeloma is diagnosed early. It has three stages, labelled I, II, and III. ...Zhong, Hao, Zhang, Jiang et al. examined the bone marrow of two healthy donors and nine people wi …
As with many types of cancer, the chance of survival is highest when multiple myeloma is diagnosed early. It has three stag …
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD Jr, Anderson KC, Zhan F, Qiu L, An G. Mao X, et al. Am J Hematol. 2024 Apr;99(4):523-533. doi: 10.1002/ajh.27207. Epub 2024 Jan 21. Am J Hematol. 2024. PMID: 38247315
Current standard predictive models of disease risk do not adequately account for the heterogeneity of survival outcomes in patients with new-diagnosed multiple myeloma (NDMM). ...In the training cohort, elevated lactate dehydrogenase level (LDH), Internationa …
Current standard predictive models of disease risk do not adequately account for the heterogeneity of survival outcomes in patients w …
A simple additive staging system for newly diagnosed multiple myeloma.
Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, Gertz MA, Baughn LB, Lacy MQ, Hayman SR, Buadi FK, Dingli D, Go RS, Hwa YL, Fonder AL, Hobbs MA, Lin Y, Leung N, Kourelis T, Warsame R, Siddiqui MA, Kyle RA, Bergsagel PL, Fonseca R, Ketterling RP, Kumar SK. Abdallah NH, et al. Blood Cancer J. 2022 Jan 31;12(1):21. doi: 10.1038/s41408-022-00611-x. Blood Cancer J. 2022. PMID: 35102148 Free PMC article.
Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and comparison of treatment approaches. ...Among 1327 evaluable patients, OS was 11.0 (95% CI: 9.2-12.6), 7.0 (95% CI: 6.3-9.2), and 4.5 (95% CI: …
Risk stratification in multiple myeloma is important for prognostication, patient selection for clinical trials, and co …
47 results